Highlights

  • Trajan Group Holdings (ASX:TRJ): FY26 Revenue declined 3.1% to AUD 161.4 million.
  • H2 FY26 normalised EBITDA reached AUD 8.1 million.
  • Second-half proforma gross Margin improved to 40.6%.
  • FY27 normalised EBITDA guidance is AUD 16.0–17.5 million.

Trajan is a Melbourne-based developer and manufacturer of analytical and life sciences products. Its portfolio spans components and consumables used in laboratories, Capital equipment for analytical science, and what it calls disruptive technologies, including tools for decentralised sample collection. Its customers include pharmaceutical, food, environmental and clinical laboratories around the world. That global footprint means currency swings, laboratory spending cycles and research budgets all feed directly.

Inside the FY26 numbers

The full-year release dated 27 August 2026, normalised group EBITDA fell 14.7 per cent to AUD 13.2 million for the year to 30 June 2026. The split, however, was stark: second-half normalised EBITDA reached AUD 8.1 million, up 61.8 per cent on the first half's AUD 5.0 million.

Second-half proforma gross margin improved to 40.6 per cent from 37.4 per cent in the first half. The company said a stronger Australian dollar cut reported revenue by about AUD 5.0 million and normalised EBITDA by about AUD 2.4 million over the year.

Cash at year end was AUD 12.6 million, and Capital Expenditure eased to AUD 3.4 million from AUD 4.1 million. The order book stood at AUD 8.7 million at 30 June 2026, while the discontinued Certus product removed roughly AUD 2.1 million of revenue.

Project Neptune and the cost base

Much of the second-half improvement came from Project Neptune, a restructuring programme covering headcount, facilities and Manufacturing footprint. Trajan said Neptune contributed about AUD 1.2 million to second-half normalised EBITDA, with a further AUD 1.2 million from lower corporate services headcount.

Other initiatives include lower Facility costs in Connecticut, greater automation, more operational transfer to Malaysia and the final phase of a global ERP rollout, including Germany. These are the levers management is relying on to lift margins further.

FY27 guidance and sector context

At the Annual General Meeting on 28 October 2026, Trajan presented FY27 guidance of net revenue between AUD 162 million and AUD 166 million and normalised EBITDA of AUD 16.0 million to AUD 17.5 million. The August release had flagged mid-single-digit organic revenue growth and double-digit EBITDA growth at prevailing exchange rates.

The broader life sciences tools sector has endured uneven Demand since the post-pandemic normalisation, with capital equipment purchases particularly sensitive to customer budgets. Trajan noted softness in its capital equipment Business during FY26, while components and consumables remained stable. Analytical science spending is also linked to pharmaceutical development pipelines and regulatory testing requirements, which tend to be steadier than discretionary equipment budgets over a full economic cycle.

Risks and what investors may be watching

Currency remains a material swing factor, as FY26 demonstrated. Execution risk also attaches to the restructuring, since savings must be delivered without disrupting customer Supply or product development.

Management has named inventory optimisation, Debt reduction and better cash conversion as capital management priorities, without publishing specific net debt targets in the results release. Developments to monitor include whether cash generation improves alongside earnings.

One development to monitor is the half-year result for the six months to 31 December 2026, which will show whether the second-half momentum of FY26 carried into the new year. For now, Trajan remains an ASX-listed small cap whose recovery case rests on cost discipline and steadier laboratory demand rather than on any single catalyst.

Key Insights

Trajan Group Holdings remains focused on the developments highlighted by its recent announcements: fY26 revenue declined 3.1% to AUD 161.4 million. FY27 normalised EBITDA guidance is AUD 16.0–17.5 million. Future disclosures will clarify the resulting operational and financial implications.